Irem brings over a decade of investing and operating experience across various stages of healthcare services and healthcare technology companies. At Norwest, she focuses on venture and growth equity opportunities across healthcare services, healthcare IT, pharma services and digital health.

Prior to joining Norwest, Irem worked at Summit Partners where she focused on healthcare growth stage businesses and was a board member or observer for four companies across risk-based providers and healthcare tech-enabled services. She was also a Principal at McKesson Ventures where she led investments in value-based care and pharma IT/services. Irem helped source or served as a board observer for Landmark Health (acquired by Optum), Aledade, IVX Health (recapped by Great Hill Partners), OncoHealth (formerly Oncology Analytics), SHYFT Analytics (acquired by Medidata), Aetion, Curana Health (formerly AllyAlign), Komodo Health, Kyruus and Evariant (acquired by Healthgrades).

Prior to joining McKesson, Irem was part of the founding team of Burd Health where she led the development and implementation of value-based initiatives for self-insured organizations across network management, pharmacy benefit management, and wellness products. She also served in product and business development roles with healthcare startups Omada Health and Caremerge (acquired by VoiceFriend) and was an intern at Andreessen Horowitz where she sourced digital health investments.

Irem started her career as an investment associate at Madison Dearborn Partners and an investment banking analyst in the Healthcare Group at Bank of America Merrill Lynch where she analyzed mergers and acquisitions for companies across life sciences, medical devices and healthcare services.

Irem holds a BS in biomedical engineering and economics, magna cum laude, from Duke University and an MBA from the Stanford Graduate School of Business, where she was an Arbuckle Leadership Fellow and Co-President of the Healthcare Club.

Dr. Zack Scott previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse.

Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical).

Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.

Manuel comes to Norwest Venture Partners with almost a decade of recruiting experience. As Senior Director of Talent, under the umbrella of Portfolio Services, Manuel works closely with growth equity and venture partners and portfolio companies.

Prior to joining Norwest, Manuel was a director at Daversa Partners where he worked closely with the Norwest team on executive searches for companies like Madison Reed, Imperfect Foods, Calm, Tempo, and Third Wave Automation.

Manuel holds a bachelor’s degree in psychology and a minor in writing from the University of California, Merced.

Brian is an experienced life sciences investor who focuses on early to mid-stage companies.

Prior to joining Norwest, Brian worked at Blackstone Life Sciences, where he helped lead over $1.5B of investments across biotech, medical devices, and diagnostics. He was a Board Observer or Alliance Committee Member at 5 companies, working closely with management teams on clinical trials, FDA approval process, and commercial strategy. Brian was previously an Engagement Manager at McKinsey & Company, where he advised companies across the healthcare industry.

Brian has a medical degree from Stanford and MBA from Harvard. His research on prostate cancer, diabetic macular edema, and patient safety has been published in multiple peer-review journals.

Tiba joins Norwest as a biotech investor with 20+ years of research and investment experience.

Based in the San Francisco office, she invests in healthcare with a focus on early to mid-stage companies within the therapeutics sector.

Prior to joining Norwest, Tiba spent over ten years at Novo Holdings A/S, one of the top life sciences investment firms, with offices in the US and Europe. In her previous role, she was responsible for the deployment of ~280M of capital in private biotech, MedTech and HCIT companies. Earlier in her career Tiba was a banker focused on M&A, licensing, and financing transactions involving biotech/pharma.

Tiba attended the University of California Irvine where she received a Bachelor of Science degree in Physics with a Biomedical concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship. Tiba is also a published author of scientific articles and book chapters in rational drug design.

Glen joined Norwest Venture Partners in 2022 as Senior Director of Editorial. In this role, he combines his journalism training with data-driven performance marketing principles to produce strategic, engaging content—in many forms—that speak directly to the entrepreneurial ecosystem.

Prior to joining Norwest, Glen was Senior Director, Content Marketing at Vonage, where he led strategic content creation and operations.

Glen graduated from the University of Massachusetts at Amherst with a B.A. in Journalism.

 

Shu Dar brings nearly two decades of expertise in Environmental, Social, and Governance (ESG) and impact investing to Norwest. As a Senior Advisor, she works closely with Norwest and its broad portfolio of companies to educate and guide them on climate change, social inequality, and related risks and opportunities.

Shu Dar is a recognized financier with experience leading organizations to identify, structure, and fundraise for environmental and social transactions. She is the Founder and Managing Partner of Lucid Capitalism, a boutique ESG and impact investing advisory practice.

At RSF Social Finance, Shu Dar led investments and served as Chairwoman of the Investment Committee, rewrote the firm’s investment policy statement and impact strategy, and oversaw the restructuring and subsequent portfolio management of its $70 million impact and ESG portfolio. Previously, she served as the Director of Capital Formation and Investor Relations at Social Finance, an impact investing firm leading Pay-for-Success project financings.

Shu Dar was a VP at Citi’s Inclusive Finance and Digital Acceleration groups where she arranged market-based poverty alleviation transactions. These included Green Bonds, and investments in cleantech and social enterprises, with a particular focus on fintech for the underbanked in Asia and Africa. At the World Bank’s IFC, she was an investor on the Global Infrastructure team and developed the $4bn Global Infrastructure Crisis Facility. She started her career as an investment banker at JPMorgan, working in Global M&A, Syndicated Leveraged Finance, and Private Equity Sponsors before and during the subprime crisis.

Shu Dar received an MBA from MIT Sloan and graduated magna cum laude from NYU Stern with a BS in Finance and International Business. Shu Dar is the daughter of immigrants and was born and raised in Pittsburgh, Pennsylvania. She lives in Bernal Heights in San Francisco with her partner and daughter.

Ryan focuses on growth equity investments across a wide range of sectors at Norwest including technology, business services, media, and consumer.

Prior to joining Norwest, Ryan was a software investor at Susquehanna Growth Equity and an investment banking analyst at Stifel/KBW. In his previous roles, he conducted valuation analyses and engaged in M&A advisory across the technology industry.

Ryan graduated from the Huntsman Program at the University of Pennsylvania, where he earned a B.S. in Economics with a concentration in Finance from the Wharton School and a B.A. in International Studies from the College of Arts and Sciences.

David focuses on early to late-stage venture investments across a wide range of sectors at Norwest, with an emphasis on the enterprise and infrastructure spaces.

Prior to joining Norwest, David worked in the technology investment banking group at Deutsche Bank, where he worked on numerous equity, debt, and M&A transactions across software, internet, and hardware verticals.

David graduated from the University of Michigan Ross School of Business with a bachelor of business administration in Finance and Accounting.

Paul focuses on early and late-stage venture investments in technology, with a particular emphasis on fintech, SaaS, and digital health. His Norwest investments include Abodu, Citcon, Exponential DeFi, Flyhomes, Noyo, Petabyte, and tvScientific.

Prior to joining Norwest, Paul was a growth investor on the technology and healthcare teams at General Atlantic in New York.

Paul graduated magna cum laude from Princeton University with a bachelor of arts degree in the Classics.